BAY 1895344 is a promising compound primarily investigated for its potential in cancer therapy. It functions as an inhibitor targeting the ATR (Ataxia Telangiectasia and Rad3-related) kinase, which plays a critical role in the DNA damage response pathway. By inhibiting ATR, this compound disrupts the ability of cancer cells to repair DNA damage, particularly in tumors with high replication stress or defects in other DNA repair mechanisms. This makes it a potential therapeutic option for cancers that are resistant to conventional treatments, such as certain types of ovarian, lung, and pancreatic cancers. Preclinical studies have shown its efficacy in sensitizing cancer cells to chemotherapy and radiation, enhancing their anti-tumor effects. Ongoing research focuses on its use in combination therapies and its application in treating cancers with specific genetic vulnerabilities.